Viridian Therapeutics Names Scott Myers CEO, Succeeding Jonathan Violin

Viridian Therapeutics, Inc. (VRDN), a biopharmaceutical company focused on medicines for serious and rare diseases, announced Monday the appointment of Scott Myers as President and Chief Executive Officer, and a member of the Board of Directors, effective today.

He succeeds Jonathan Violin, who has led Viridian since its inception in 2020.

Myers has more than 30 years of biopharmaceutical and medical technology experience. He most recently served as the CEO and Director of AMAG Pharmaceuticals, where he led its turnaround and strategic sale to Covis Pharma.

Prior to AMAG, he served as CEO and Chairman of the Board of Rainier Therapeutics, a late-stage oncology company.

He had also worked as CEO of Cascadian Therapeutics until its acquisition by Seagen, and Aerocrine AB, a medical technology company.

Myers is currently on the board of directors at Dynavax Technologies, Harpoon Therapeutics, Ironshore Therapeutics, Selecta Biosciences, and Sensorion. He was previously an Independent Director at Trillium Therapeutics until its acquisition by Pfizer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines and Archer Aviation Inc. announced plans to launch the first commercial electric air taxi route in Chicago, between O'Hare International Airport or ORD and Vertiport Chicago. As part of their urban air mobility or UAM network buildout, both companies will utilize Archer's electric vertical takeoff and landing or eVTOL aircraft in the new route. Fort Wayne, Indiana-based Perfection Bakeries D/B/A Aunt Millie's is recalling 8 ct. packages of Our Family White Hot Dog Buns citing the possible presence of undeclared sesame, a known allergen, the U.S. Food and Drug Administration said. The product comes in a printed plastic package marked with "Our Family Hot Dog Buns 8 ct." on the top and has a blue twist tie. Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.
Follow RTT